The news of Canaccord Genuity maintaining a Buy rating and raising the price target for Sigilon Therapeutics from $6 to $30 is likely to have a positive impact on the company's stock in the short term. This is because such an upgrade usually signals the analyst's increased confidence in the company's future performance, which can attract more investors and drive up the stock price.